Christopher Colopinto, DO
Family Medicine · Camden, NJNPI 1659341923
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,554 of the $19,651 with a category attached, or 79.2%. It is spread thinly across 56 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $6,945 and has fallen 59.0% since, to $2,848 in 2025. Among family medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,013 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Johnson & Johnson$3K
- Amgen$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- AbbVie$1K
- Kowa Pharmaceuticals America, Inc.$1K
- plus $7K from 50 others
What the payments were for
- Speaking & faculty fees$3,31517%
- Travel & lodging$3922%
- Food & beverage$15,55479%
- Education$3902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,651 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 128 | $126,777 |
| OzempicSemaglutide | 81 | $107,030 |
| EliquisApixaban | 130 | $106,364 |
| FarxigaDapagliflozin Propanediol | 107 | $104,235 |
| XareltoRivaroxaban | 46 | $64,111 |
| ZenpepLipase/Protease/Amylase | 22 | $53,134 |
| MounjaroTirzepatide | 28 | $47,334 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $36,245 |
| RexultiBrexpiprazole | 17 | $29,738 |
| JanuviaSitagliptin Phosphate | 22 | $23,563 |
| UbrelvyUbrogepant | 19 | $19,608 |
| TrintellixVortioxetine Hydrobromide | 21 | $18,023 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $15,647 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $14,270 |
| LinzessLinaclotide | 12 | $12,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $548 | $137,343144 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $3,059 | $122,267143 claims |
| Novo NordiskOzempic | $686 | $107,03081 claims |
| PfizerEliquis | $529 | $106,364130 claims |
| Johnson & JohnsonXarelto | $2,519 | $64,11146 claims |
| Aimmune Therapeutics, Inc.Zenpep | $14 | $53,13422 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $169 | $47,48787 claims |
| Lilly USA, LLCMounjaro | $214 | $47,33428 claims |
| AbbVieUbrelvy, Linzess | $1,348 | $32,21531 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $570 | $29,73817 claims |
| MerckJanuvia | $673 | $23,56322 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,846 | $18,02321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Camden
- Mikhail VarshavskiChatham$1.4M
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
- Jennifer CaudleSewell$226K
- Jeffrey LevineNew Brunswick$195K
- Jennifer AmicoNew Brunswick$159K
- Dena LacaraFairfield$122K
- Gaurang BrahmbhattHoboken$89K
- Juan LatorreHoboken$71K
- Sally MravcakJersey City$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.